TY - JOUR AU - Anthony R. Mato, AU - William G. Wierda, AU - Matthew S. Davids, AU - Bruce D. Cheson, AU - Steven E. Coutre, AU - Michael Choi, AU - Richard R. Furman, AU - Leonard Heffner, AU - Paul M. Barr, AU - Herbert Eradat, AU - Sharanya M. Ford, AU - Lang Zhou, AU - Maria Verdugo, AU - Rod A. Humerickhouse, AU - Jalaja Potluri, AU - John C. Byrd, PY - 2019/10/30 Y2 - 2024/03/29 TI - Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy JF - Haematologica JA - haematol VL - 104 IS - 11 SE - Articles DO - 10.3324/haematol.2018.207068 UR - https://haematologica.org/article/view/9128 SP - 2258-2264 AB - The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter’s transformation versus chronic lymphocytic leukemia (CLL) progression after ibrutinib and/or idelalisib was assessed in a post hoc analysis of a phase II study of venetoclax. Patients underwent PET-CT at screening and were not enrolled/treated if Richter’s transformation was confirmed pathologically. Of 167 patients screened, 57 met criteria for biopsy after PET-CT. Of 35 patients who underwent biopsy, eight had Richter’s transformation, two had another malignancy, and 25 had CLL. A PET-CT maximum standardized uptake value (SUVmax) ≥10 had 71% sensitivity and 50% specificity for detecting Richter’s transformation [Odds Ratio (OR): 2.5, 95%CI: 0.4-15; P=0.318]. Response rate to venetoclax was similar for screening SUVmax